Efficacy of Nebulized Pentoxifylline in a Mouse Model of Emphysema Induced by Cigarette Smoke and Aerosolized Lipopolysaccharide

Read full text
Authors: Zhenghao Hu, Yaling Yu, Tianfeng Peng, Ruijie Niu, Zhuanyun Li, Wenjing Wang, Xiaofang Zheng, Jinnong Zhang
Cited by: 1
References: 43

Abstract

Objective: To investigate the impact of pentoxifylline dosage on lung pathological changes and inflammation triggered by the combined exposure to cigarette smoke and aerosolized lipopolysaccharides. Methods: Female C57BL/6 mice were subjected to either cigarette smoke (CS) plus lipopolysaccharide (LPS) exposure or sham smoke (SCS) exposure for a duration of 10 weeks. Starting from the 9th week, the mice were randomly assigned to distinct intervention groups, where they received nebulized treatments of pentoxifylline (at varying doses), theophylline, or budesonide suspension for 2 weeks. A co-solvent control group was also included. At the end of the 10th week, the mice were euthanized. Enzyme-linked immunosorbent assay (ELISA) was employed to detect the expression levels of tumor necrosis factor-α (TNF-α), keratinocyte chemoattractant/C-X-C motif chemokine ligand 1 (KC/CXCL1, the murine functional homolog), and interleukin-1β (IL-1β) in bronchoalveolar lavage fluid (BALF). After tissue homogenization, ELISA was also used to measure the expression of matrix metalloproteinase-12 (MMP-12) and the level of histone deacetylase 2 (HDAC2). Hematoxylin and eosin (H&E) staining was performed on lung tissue sections to determine the alveolar mean linear intercept (Lm) and alveolar destruction index (ADI). Additionally, Wright-Giemsa staining was utilized for the classification and quantification of cells in BALF. Results: Chronic exposure to CS+LPS resulted in a significant exacerbation of pulmonary inflammation, which was characterized by elevated levels of TNF-α, KC/CXCL1, IL-1β, and MMP-12 (CS+LPS group vs SCS group, all p

Fields of Study & Subjects

Chronic Obstructive Pulmonary Disease (COPD) Research Asthma and respiratory diseases Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Publication details

Journal / source
International Journal of COPD
Publisher
Informa UK Limited
Volume
Volume 21
Pages
1–16
Publication date
1 January 2026
Language
EN